Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3050258 in Healthy Volunteers
NCT02121834Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing LY3050258 with Placebo (2 arms). Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration at 14 weeks. Started Jun 2014; status: completed.
02
Drugs
LY3050258
Beyond the preview
Go deeper on NCT02121834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121834.